Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Research Abstract |
Glaucoma, the most major cause of vision loss in Japan, is characterized by progressive visual field loss due to loss of retinal ganglion cells. Inhibitors for VCP has been elucidated to have neuroprotective effect and to delay disease progression on mouse models of glaucoma. They might be new neuroprotective drugs for glaucoma patients.
|